# Meningococcal Conjugate C Vaccine (Mencon-C)

Revision Date: August 7, 2014

Please consult the Product Monograph\(^1\) for further information about the vaccine.

<table>
<thead>
<tr>
<th><strong>MENJUGATE®</strong></th>
<th><strong>NeisVac-C®</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer</td>
<td>Novartis Vaccines and Diagnostics S.r.l.; distributed by Novartis Pharmaceuticals Canada Inc.</td>
</tr>
<tr>
<td>Licensed use</td>
<td>Infants 2 – 12 months should receive three doses with an interval of at least one month between doses and a booster dose following the completion of the series.(^1)</td>
</tr>
<tr>
<td>Off-license use</td>
<td>Infants 2 – 11 months of age inclusive receive one dose at four months of age followed by a dose in the second year of life at 12 months of age.(^2)</td>
</tr>
</tbody>
</table>

## Indications for use of provincially funded vaccine

**Pre-exposure:**
- Infants and children two months up to and including 59 months of age\(^3\) (routine infant and pre-school program).
  - **Note:** Infants and children at high risk due to underlying medical conditions should receive meningococcal quadrivalent vaccine groups A, C, Y and W-135 (MenC-ACYW) not meningococcal group C vaccine (MenconC).\(^3\) See Menveo® (2 – 23 months of age) and Menveo® Menactra®, or Nimenrix® (24 months of age and older). Biological Products - MenC-ACYW Vaccine.

**Post-exposure:**
- Immunization or re-immunization of close contacts of laboratory-confirmed cases of serogroup C invasive meningococcal disease.\(^3\) See scheduling section for further details.
  - **Note:** Results of index case serogroup should be known (generally within 2 to 5 days) before proceeding with immunization.
- Outbreak control of laboratory confirmed serogroup C invasive meningococcal disease.\(^3\)

For disease information, contact assessment and reporting guidelines refer to *Public Health Notifiable Disease Management Guidelines - Meningococcal Disease, Invasive*\(^4\).

## Dose

- 0.5 mL

## Route

- Intramuscular injection

## Schedule

**Pre-exposure**
- Routine infant/preschool program (2 – 59 months of age inclusive):
  - Dose 1: 4 months of age\(^4\)
  - Dose 2: 12 months of age and at least four weeks after dose 1
Notes:
- Infants and children at high risk due to underlying medical conditions should receive MenC-ACYW. MenconC is not recommended in addition to MenC-ACYW.
- Children with delayed immunization beginning immunization at 12 months of age or older require only one dose.

The first dose of vaccine should not be administered before two months (eight weeks) of age.

Post-exposure:

2 months – 11 months of age
- Unimmunized: administer one dose.
- Previous immunization: administer one dose if at least four weeks since the previous dose.

12 months – 10 years of age:
- Unimmunized: administer one dose.
- Previously immunized at younger than 12 months of age or at high risk due to an underlying medical condition: administer one dose if at least four weeks since the last dose.
- Previously immunized at 12 months or older: administer one dose if at least one year since the last dose.

11 years of age and older:
- Unimmunized: administer one dose.
- Previously immunized at younger than 12 months of age or at high risk due to an underlying medical condition: administer one dose if at least four weeks since the last dose.
- Previously immunized at 12 months of age or older: administer one dose if at least one year since the last dose.

Note: Use MenC-ACYW post-exposure for meningococcal C if the individual is eligible for the MenC-ACYW vaccine (e.g., a student in Grades 9, 10, 11 or 12 who has not already received their adolescent MenC-ACYW vaccine).

Contraindications
- Known severe hypersensitivity to any component of the vaccine or its container.
- Anaphylactic or other allergic reactions to a previous dose of vaccine containing meningococcal conjugate C antigen.

Precautions
- Immunization with this vaccine should not be considered as an immunizing agent against diphtheria.
- Provides protection only against serotype C meningococcal disease.

Possible reactions
See Product Monograph

Pregnancy
Meningococcal C conjugate vaccine has not been studied in pregnant women; however, in specific situations as outlined above (post-exposure) the vaccine should be administered when indicated.

Lactation
Breastfeeding women should receive vaccine if indicated.

Program Notes
- 2001 November 1 – 2002 March 31 – Offered as part of mass immunization campaign to infants 2 to 24 months of age.
• 2002 April 4 - Meningococcal Conjugate C (Menjugate®) – Routine childhood immunization schedule for infants born on or after 2001 September 1
• 2015 January 1 – Schedule change from 3 doses given at 2, 4 and 12 months of age to 2 doses given at 4 and 12 months of age.

References
1 Novartis Vaccines and Diagnostics S.r.l. and Novartis Pharmaceuticals Canada Inc. (2013, February 21). MENJUGATE®: Meningococcal group C-CRM197 conjugate vaccine. Product Monograph.